Open for claimsSecuritiesEdwards Lifesciences securities settlement claims are due December 2, 2026
Last updated:
Sources last checked:
The proposed $39 million cash settlement covers federal securities claims about statements concerning growth of Edwards Lifesciences’ transcatheter aortic valve replacement business. It applies to people and entities that acquired Edwards common stock during the class period and were damaged.
Approved claimants receive a proportional share of the net fund based on recognized losses. Under the proposed plan, shares must have been held through the close of trading on July 24, 2024 to produce a recognized loss. A distribution calculated below $10 will not be made.
Key facts
- Class period
- February 6 through July 24, 2024, inclusive
- Fund
- $39 million gross, before taxes, notice, administration and court-approved fees and expenses
- Claim deadline
- Submit online or postmark by December 2, 2026
- Court case
- Patel v. Edwards Lifesciences Corporation, Central District of California, No. 8:24-cv-02221-AH-KES
- Hearing
- Scheduled for December 16, 2026 at 1:30 p.m. Pacific
Official settlement administrator: Kroll Settlement Administration
Evidence for key facts
These excerpts record what official sources said when checked. Open a fact to see its source and supporting passage. Follow the source for the latest information.
Claim statusChecked
have reached a proposed settlement of the Action for $39,000,000 in cash
Court-authorized notice (public copy hosted by Class Action Tracker)PDF p. 1, notice of proposed settlement
Who qualifiesChecked
all persons or entities who purchased or otherwise acquired Edwards common stock during the period from February 6, 2024 through July 24, 2024, inclusive
Court-authorized notice (public copy hosted by Class Action Tracker)PDF p. 8, paragraph 30
Payment and benefitsChecked
cash payment of $39,000,000 (“Settlement Amount”) to be deposited into an escrow account.
Court-authorized notice (public copy hosted by Class Action Tracker)PDF p. 2, paragraph 2
Proof requirementsChecked
required to submit a Claim Form and the required supporting documentation as set forth in
Court-authorized notice (public copy hosted by Class Action Tracker)PDF p. 8, instructions following paragraph 30
Claim deadlineChecked
the Claim Form postmarked (if mailed), or online at www.EdwardsLifesciencesSecuritiesLitigation.com, no later than December 2, 2026.
Court-authorized notice (public copy hosted by Class Action Tracker)PDF p. 9, continuation of instructions
Who qualifies
- The class covers persons and entities that bought or otherwise acquired Edwards common stock during the class period and were damaged. The filed class definition imposes no separate state-of-residence condition.
- Excluded are the defendants, their successors and assigns, their past and current executive officers and directors (including former individual defendants), and the specified immediate family members of the individual defendants. Entities in which an excluded person has or had a direct or controlling ownership interest, the legal representatives, heirs, successors and assigns of excluded persons or entities, and people whose exclusion requests are accepted by the court are also excluded.
How to submit a claim
- 1
Identify the beneficial owner
Complete Kroll’s Proof of Claim and Release Form in the beneficial owner’s name. Joint owners must both sign. A representative must identify the owner and supply proof of authority.
- 2
Document holdings and transactions
Complete the transaction and holdings schedules and attach copies of brokerage confirmations, account statements or equivalent records. Include the requested beginning and ending holdings and subsequent transactions needed to balance the claim. Sign the certification.
- 3
Submit by December 2
Submit online on the settlement website or mail the signed form and copies of the records to Edwards Lifesciences Securities Litigation, c/o Kroll Settlement Administration, PO Box 5014, New York, NY 10150-5014. Mailed claims must be postmarked by December 2, 2026. For help, call 1-833-930-0555.
Find more settlements you may qualify for.
ClaimBee matches your profile against 2,000+ active settlements, shows payout and proof requirements up front, and tracks every deadline for you.
Frequently asked questions
Is there a fixed amount per share?
No. The plan calculates recognized losses using trading dates and prices. The actual payment depends on the net fund and the total recognized claims accepted.
Does any purchase during the period qualify for a payment?
A purchase or acquisition during the class period and a qualifying loss are required. The plan gives zero recognized loss to shares sold before the close of trading on July 24, 2024.
When will the settlement pay?
Payment depends on final approval, resolution of appeals and completion of claim processing. The hearing date does not establish a payment date.
Sources and official records
Consult these records for the official terms and current updates. ClaimBee's summary helps explain the settlement; the administrator and court documents determine the claim requirements and benefits.
Related settlements
Open for claims · Securities
Marqeta Securities Settlement
Pro rata share of the net fund for approved recognized losses; calculated payments below $10 are not distributed · Must be received by December 31, 2026
Open for claims · Securities
Anadarko Petroleum Securities Settlement
Pro rata by recognized loss; no distribution below $10 · January 21, 2027 (online or mail postmark)
More settlements people are checking
Payout status for other settlements we track, updated as administrators publish new information.